Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2020 Results and Provides General Corporate Update
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) announced its Q4 and full-year 2020 results, signaling progress in its clinical programs. The FDA cleared the IND application for its lead candidate AP-PA02, aimed at treating Pseudomonas aeruginosa infections. The company appointed Robin C. Kramer to its Board and Mina Pastagia as VP of Clinical Development. Financially, Armata reported Q4 revenues of $0.5 million and a loss from operations of $6.5 million. After raising $20 million from Innoviva, the company has approximately $9.7 million in cash, sufficient to fund operations into Q1 2022.
- FDA cleared IND for AP-PA02, enhancing clinical prospects.
- Raised $20 million from Innoviva, improving financial stability.
- Strengthened leadership with key appointments.
- Loss from operations increased to $(21.6) million in 2020.
- Research and development expenses surged to $14.4 million, up from $9.8 million.
MARINA DEL REY, Calif., March 18, 2021 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced results for the fourth quarter and full year 2020 and provided a corporate and clinical update.
Fourth Quarter 2020 and Recent Highlights:
- Announced FDA clearance of Investigational New Drug (IND) application to initiate Phase 1b/2a SWARM-P.a. clinical trial of lead candidate AP-PA02 in Pseudomonas aeruginosa infections
- Appointed biotechnology finance veteran Robin C. Kramer to its Board of Directors
- Hired Mina Pastagia, M.D., M.S., as Vice President of Clinical Development, adding significant expertise in the field of anti-infective development, including phage-based therapeutics
- Subsequent to the end of the fourth quarter 2020, the Company raised gross proceeds of
$20.0 million through a securities purchase agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata's largest shareholder
"During the fourth quarter and subsequent period, we made great progress across all aspects of our business," stated Todd R. Patrick, Chief Executive Officer of Armata. "We took a significant step forward in the clinical development of our lead candidate, AP-PA02, and strengthened both our Board and leadership team. We also solidified our balance sheet which, together with remaining funds from the non-dilutive contract awards that we received last year, provide the resources to achieve meaningful milestones both this year and next.
"Looking ahead, in addition to initiating a Phase 1b/2 trial of AP-SA02 in Staphylococcus aureus bacteremia infections, we are also working toward the initiation of additional clinical trials assessing phage-based candidates in difficult to treat pathogens. Indications we are exploring include non-cystic fibrosis bronchiectasis, pneumonia and prosthetic joint infection. With an efficient clinical plan targeting several distinct indications, we believe we can play a key role in the advancement of phage therapy as a viable answer to the rise of antimicrobial resistance," Mr. Patrick concluded.
Anticipated 2021 and 2022 Milestones:
- Complete the single ascending dose (SAD) cohort of the SWARM-P.a. Phase 1b/2a clinical trial evaluating AP-PA02 as a potential treatment for Pseudomonas aeruginosa infections in the coming months
- Initiate and complete the multiple ascending dose (MAD) cohort of SWARM-P.a. trial in late 2021/early 2022
- Initiate a Phase 1b/2 clinical trial evaluating AP-SA02 as a potential treatment for Staphylococcus aureus bacteremia
- Initiate at least one additional clinical trial using either of its two lead phage product candidates or slightly altered mixtures of phage products in an additional indication
Fourth Quarter Financial Results
Grant Revenue. The Company recognized grant revenue of
Research and Development. Research and development expenses for the three months ended December 31, 2020 were approximately
General and Administrative. General and administrative expenses for the three months ended December 31, 2020 were
Loss from Operations. Loss from operations for the three months ended December 31, 2020 was
Cash and Equivalents. As of December 31, 2020, Armata held approximately
The audit opinion included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020 contains a going concern explanatory paragraph.
As of March 18, 2021, there were approximately 24.9 million shares of common stock outstanding.
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Forward Looking Statements
This communication contains "forward-looking" statements, including, without limitation, statements related to the use of proceeds from the securities offering, Armata's bacteriophage development programs, Armata's ability to meet expected milestones, Armata's ability to be a leader in the development of phage-based therapeutics, and statements related to the timing and results of clinical trials, including the anticipated initiation of clinical trials of AP-PA02 and AP-SA02, Armata's ability to develop new products based on bacteriophages and synthetic phages, and Armata's expectations for performance of Armata's therapeutic candidates based on Armata's recent nonclinical work. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Armata's current expectations. Forward-looking statements involve risks and uncertainties. Armata's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the ability of Armata's lead clinical candidates, AP-PA02 and AP-SA02, to be more effective than previous candidates; Armata's ability to expedite development of AP-PA02; Armata's ability to advance its preclinical and clinical programs and the uncertain and time-consuming regulatory approval process; Armata's ability to develop products based on bacteriophages and synthetic phages to kill bacterial pathogens; the Company's expected market opportunity for its products; Armata's ability to sufficiently fund its operations as expected, including obtaining additional funding as needed; and any delays or adverse events within, or outside of, Armata's control, caused by the recent outbreak of COVID-19. Additional risks and uncertainties relating to Armata and its business can be found under the caption "Risk Factors" and elsewhere in Armata's filings and reports with the SEC, including in Armata's Annual Report on Form 10-K, filed with the SEC on March 18, 2021, and in its subsequent filings with the SEC.
Armata expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Armata's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts:
At Armata:
Steve Martin
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
858-800-2492
Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569
Armata Pharmaceuticals, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
December 31, 2020 | December 31, 2019 | |||||
Assets | ||||||
Cash and cash equivalents | $ | 9,649,000 | $ | 6,033,000 | ||
Awards receivable | 561,000 | 94,000 | ||||
Prepaids and other current assets | 636,000 | 528,000 | ||||
Total current assets | 10,846,000 | 6,655,000 | ||||
Property and equipment, net | 12,837,000 | 4,214,000 | ||||
Other long term assets | 2,087,000 | 836,000 | ||||
Intangible assets, net | 13,746,000 | 13,746,000 | ||||
Total assets | $ | 39,516,000 | $ | 25,451,000 | ||
Liabilities and stockholders' equity | ||||||
Total current liabilities | $ | 6,705,000 | $ | 4,879,000 | ||
Long term liabilities | 10,877,000 | 2,902,000 | ||||
Deferred tax liability | 3,077,000 | 3,077,000 | ||||
Total liabilities | 20,659,000 | 10,858,000 | ||||
Stockholders' equity | 18,857,000 | 14,593,000 | ||||
Total liabilities and stockholders' equity | $ | 39,516,000 | $ | 25,451,000 | ||
Armata Pharmaceuticals, Inc. | ||||||||||||
Condensed Consolidated Statements of Operations | ||||||||||||
Three Months Ended Dec 31, | Twelve Months Ended Dec 31, | |||||||||||
2020 | 2019 | 2020 | 2019 | |||||||||
(Unaudited) | (Unaudited) | |||||||||||
Grant Revenue | $ | 504,000 | $ | - | $ | 823,000 | $ | - | ||||
Operating expenses: | ||||||||||||
Research and development | 4,980,000 | 1,668,000 | 14,444,000 | 9,824,000 | ||||||||
General and administrative | 1,977,000 | 2,045,000 | 7,966,000 | 9,265,000 | ||||||||
Loss on sale of assets | - | 663,000 | 663,000 | |||||||||
Total operating expenses | 6,957,000 | 4,376,000 | 22,410,000 | 19,752,000 | ||||||||
Loss from operations | (6,453,000) | (4,376,000) | (21,587,000) | (19,752,000) | ||||||||
Other income (expense): | ||||||||||||
Change in fair value of derivative liabilities | - | - | - | 1,117,000 | ||||||||
Other income (expense), net | (171,000) | (210,000) | (594,000) | (844,000) | ||||||||
Total other income (expense), net | (171,000) | (210,000) | (594,000) | 273,000 | ||||||||
Loss before income taxes and Net Loss | $ | (6,624,000) | $ | (4,586,000) | $ | (22,181,000) | $ | (19,479,000) | ||||
Net loss per share, basic | $ | (0.36) | $ | (0.48) | $ | (1.35) | $ | (2.49) | ||||
Weighted average shares outstanding, basic | 18,422,821 | 9,579,265 | 16,415,012 | 7,827,197 | ||||||||
Net loss per share, diluted | $ | (0.36) | $ | (0.48) | $ | (1.35) | $ | (2.55) | ||||
Weighted average shares outstanding, diluted | 18,422,821 | 9,579,265 | 16,415,012 | 8,009,909 | ||||||||
Armata Pharmaceuticals, Inc. | |||||||
Condensed Consolidated Statements of Cash Flows | |||||||
Twelve Months Ended Dec 31, | |||||||
2020 | 2019 | ||||||
Operating activities: | |||||||
Net loss | $ | (22,181,000) | $ | (19,479,000) | |||
Adjustments required to reconcile net loss to net cash used in operating activities: | |||||||
Change in fair value of derivative liabilities | - | (1,117,000) | |||||
Stock-based compensation | 3,475,000 | 4,271,000 | |||||
Depreciation | 1,114,000 | 1,351,000 | |||||
Non-cash interest expense | 628,000 | 918,000 | |||||
Payment of accreted interest for deferred consideration for asset acquisition | (432,000) | - | |||||
Changes in operating assets and liabilities, net | (874,000) | (1,526,000) | |||||
Net cash used in operating activities | (18,270,000) | (15,582,000) | |||||
Investing activities: | |||||||
Purchases of property and equipment, net | (824,000) | (131,000) | |||||
Cash acquired in reverse merger transaction | - | 3,008,000 | |||||
Net cash used in investing activities | (824,000) | 2,877,000 | |||||
Financing activities: | |||||||
Prinicpal payment of deferred consideration for asset acquisition | (568,000) | (1,000,000) | |||||
Proceeds from sale of common stock, net of offering costs | 22,893,000 | 9,975,000 | |||||
Proceeds from exercise of warrants and stock options | 168,000 | - | |||||
Proceeds from PPP Loan | 717,000 | - | |||||
Net cash provided by (used in) financing activities | 23,210,000 | 8,975,000 | |||||
Net increase (decrease) in cash and cash equivalents | 4,116,000 | (3,730,000) | |||||
Cash, cash equivalents and restricted cash, beginning of period | 6,733,000 | 10,463,000 | |||||
Cash, cash equivalents and restricted cash, end of period | $ | 10,849,000 | $ | 6,733,000 | |||
Reconciliation of Cash and cash equivalents: | Twelve Months Ended Dec 31, | ||||||
2020 | 2019 | ||||||
Cash and cash equivalents | $ | 9,649,000 | $ | 6,033,000 | |||
Restricted cash | 1,200,000 | 700,000 | |||||
Cash, cash equivalents and restricted cash | $ | 10,849,000 | $ | 6,733,000 | |||
View original content to download multimedia:http://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-fourth-quarter-and-full-year-2020-results-and-provides-general-corporate-update-301250529.html
SOURCE Armata Pharmaceuticals, Inc.
FAQ
What were Armata Pharmaceuticals' Q4 2020 financial results?
What significant clinical developments occurred for ARMP in 2021?
How much did Armata Pharmaceuticals raise in their recent funding round?
What is Armata's current financial situation as of March 2021?
What is the stock symbol for Armata Pharmaceuticals?
